TITLE

Inimex Nets $22M to Advance Innate Defense

PUB. DATE
June 2008
SOURCE
Bioworld Week;6/9/2008, Vol. 16 Issue 23, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Inimex Pharmaceuticals Inc. of Vancouver, British Columbia has raised $22 million to advance its portfolio which includes products for combating antibiotic resistance and inflammation. The company is developing a series of non-antibiotic drugs designed to trigger the body's defenses against infection. Furthermore, the company's technology counteracts inflammation, which is the major side effect of other immune-boosting medications.
ACCESSION #
32658361

 

Related Articles

  • Effect of L. plantarum cell-free extract and co-trimoxazole against Salmonella Typhimurium: a possible adjunct therapy. Rishi, Praveen; Preet, Simran; Kaur, Prabhjot // Annals of Clinical Microbiology & Antimicrobials;2011, Vol. 10 Issue 1, p9 

    Background: Frequent and indiscriminate use of antibiotics has led to the development of multi-drug resistant bacterial strains. It necessitates the exploitation of alternative therapeutic strategies. In order to reduce the dose of antibiotic required and to decrease the associated side effects,...

  • Integration of Diverse Data Sources for Prediction of Adverse Drug Events. Abernethy, D R; Bai, J P F; Burkhart, K; Xie, H-G; Zhichkin, P // Clinical Pharmacology & Therapeutics;Nov2011, Vol. 90 Issue 5, p645 

    The rapid evolution of large biological, pharmacological, and chemical databases has led to optimism that such data resources can be leveraged for prediction of drug action based on molecular descriptors of the drug. Challenges to realize this possibility include organization of each type of...

  • Evaluating cardiac risk: exposure response analysis in early clinical drug development. Grenier, Julie; Paglialunga, Sabina; Morimoto, Bruce H; Lester, Robert M // Drug, Healthcare & Patient Safety;Apr2018, Vol. 10, p27 

    The assessment of a drug's cardiac liability has undergone considerable metamorphosis by regulators since International Council for Harmonization of Technical Requirement for Pharmaceuticals for Human Use E14 guideline was introduced in 2005. Drug developers now have a choice in how...

  • Oseltamivir.  // Reactions Weekly;12/4/2010, Issue 1330, p27 

    The article describes the case of two immunocompromised patients who developed resistance against oseltamivir while undergoing treatment for influenza A virus H1N1 subtype.

  • Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery. Bionda, Nina; Cudic, Predrag // Croatica Chemica Acta;Sep2011, Vol. 84 Issue 2, p315 

    Naturally occurring cyclic depsipeptides, microbial secondary metabolites that contain one or more ester bonds in addition to the amide bonds, have emerged as an important source of pharmacologically active compounds or promising lead structures for the development of novel synthetically derived...

  • Treatment of Visceral Leishmaniasis. Moore, E. M.; Lockwood, D. N. // Journal of Global Infectious Diseases;May2010, Vol. 2 Issue 2, p151 

    The available treatment options for visceral leishmaniasis (VL) have problems relating to efficacy, adverse effects and cost, making treatment a complex issue. We review the evidence relating to the different methods of treatment in relation to - efficacy and toxicity of the drugs in different...

  • Nephrotoxicity risk with vancomycin use. Pfeiffer, Naomi // Dermatology Times;Jul2001, Vol. 22 Issue 7, p3 

    Cites research findings on the risks of nephrotoxicity among critically ill hospital patients treated with vancomycin. Vulnerability of the sickest of the patients to renal damage; Research efforts to develop better ways of managing drug-resistant organisms.

  • INIMEX RAISES US $22 MIL AGAINST ANTIBIOTIC RESISTANCE.  // Biotech Financial Reports;Jul2008, Vol. 15 Issue 7, p1 

    The article reports on the $22 million venture funds received by Inimex Pharmaceuticals, Inc. The venture funds allow Inimex Pharmaceuticals, Inc. to conduct clinical trials of an Innate defense Regulator (IDR) drug in patients. They are donated by several investors including Morningside Venture...

  • Inimex Nets $22M in Series B to Advance Innate Defense Drugs. Turner, Tiffany // BioWorld Today;6/3/2008, Vol. 19 Issue 107, p1 

    The article talks about the successful Series B financing held by Inimex Pharmaceuticals Inc., that it expects to bring it closer to conducting clinical trials of its Innate Defense Regulator drugs. The company raised $22 million to grow its portfolio, which includes a number of potential...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics